Götz Laible, Sally Cole, Brigid Brophy, Paul Maclean, Li How Chen, Dan P Pollock, Lisa Cavacini, Nathalie Fournier, Christophe De Romeuf, Nicholas C Masiello, William G Gavin, David N Wells, Harry M Meade
Therapeutic monoclonal antibodies (mAbs) represent one of the most important classes of pharmaceutical proteins to treat human diseases. Most are produced in cultured mammalian cells which is expensive, limiting their availability. Goats, striking a good balance between a relatively short generation time and copious milk yield, present an alternative platform for the cost-effective, flexible, large-scale production of therapeutic mAbs. Here, we focused on cetuximab, a mAb against epidermal growth factor receptor, that is commercially produced under the brand name Erbitux and approved for anti-cancer treatments...
November 2020: FASEB BioAdvances